alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 02-7549

LAWRENCE GENE LANZY,

Petitioner - Appellant,

versus

RICKIE HARRISON, Warden of Kershaw

Correctional Institution; GARY D. MAYNARD,

Director of South Carolina Department of

Corrections; CHARLES M. CONDON, Attorney

General of the State of South Carolina,

Respondents - Appellees.

Appeal from the United States District Court for the District of

South Carolina, at Florence. Margaret B. Seymour, District Judge.

(CA-01-3652-24BH-4)

Submitted: November 21, 2002 Decided: December 9, 2002

Before NIEMEYER, WILLIAMS, and TRAXLER, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Lawrence Gene Lanzy, Appellant Pro Se. Samuel Creighton Waters,

OFFICE OF THE ATTORNEY GENERAL OF SOUTH CAROLINA, Columbia, South

Carolina, for Appellees.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
2

PER CURIAM:

Lawrence Gene Lanzy seeks to appeal the district court’s order

denying relief on his petition filed under 28 U.S.C. § 2254 (2000).

We have reviewed the record and conclude for the reasons stated by

the district court that Lanzy has not made a substantial showing of

the denial of a constitutional right. See Lanzy v. Harrison, No.

CA-01-3652-24BH-4 (D.S.C. Sept. 25, 2002). Accordingly, we deny a

certificate of appealability and dismiss the appeal. See 28 U.S.C.

§ 2253(c) (2000). We also deny Lanzy’s “Motion to Accept Exhibit

Evidence.” We dispense with oral argument because the facts and

legal contentions are adequately presented in the materials before

the court and argument would not aid the decisional process.

DISMISSED
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS OF AMERICAN GAMING &
ENTERTAINMENT, LTD. FOR THE THREE MONTH PERIOD ENDED MARCH 31, 1999 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               MAR-31-1999
<CASH>                                         622,000
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             6,916,000
<PP&E>                                      12,681,000
<DEPRECIATION>                               5,657,000
<TOTAL-ASSETS>                              13,940,000
<CURRENT-LIABILITIES>                       76,720,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                 16,687,000
<COMMON>                                       126,000
<OTHER-SE>                                (80,539,000)
<TOTAL-LIABILITY-AND-EQUITY>                13,940,000
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                               778,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           1,152,000
<INCOME-PRETAX>                            (1,863,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,863,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (2,330,000)
<EPS-BASIC>                                   (0.19)
<EPS-DILUTED>                                   (0.19)


</TABLE>
Jason H. AGUILERA, petitioner, v. UNITED STATES.

No. 16-6491.

Supreme Court of the United States

Nov. 28, 2016.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
[Federal Register Volume 66, Number 117 (Monday, June 18, 2001)]
[Notices]
[Page 32830]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-15253]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Initial Review 
Group Subcommittee G--Education.
    Date: June 26-28, 2001.
    Time: 9 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Holiday Inn, Chevy Chase, 5520 Wisconsin Avenue, Chevy 
Chase, MD 20815.
    Contact Person: Harvey P. Stein, PhD., Scientific Review 
Administrator, Grants Review Branch, Division of Extramural 
Activities, National Cancer Institute, National Institutes of 
Health, 6116 Executive Boulevard, room 8137, (301) 496-7841.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.


    Dated: June 11, 2001.
Anna P. Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 01-15253 Filed 6-15-01; 8:45 am]
BILLING CODE 4140-01-M
[Federal Register Volume 66, Number 121 (Friday, June 22, 2001)]
[Notices]
[Page 33548]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-15763]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Nursing Research; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Nursing Research 
Special Emphasis Panel.
    Date: June 21, 2001.
    Time: 5:30 p.m. to 6:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Holiday Inn--Silver Spring, 8777 Georgia Avenue, Silver 
Spring, MD 20910.
    Contact Person: John Richters, Scientific Review Administrator, 
National Institute of Nursing Research, National Institutes of 
Health, Natcher Building, Room 3AN32, Bethesda, MD 20892, (301) 594-
5971.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.361, 
Nursing Research, National Institutes of Health, HHS)

    Dated: June 18, 2001.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 01-15763 Filed 6-21-01; 8:45 am]
BILLING CODE 4140-01-M
Exhibit










Exhibit 10.1



September 18, 2015


Parag Shah


Dear Parag,
The success of Bellerophon Therapeutics is the result of the commitment and unique skills of professionals like you. Retaining the right people is essential to achieving our objectives for patients and shareholders and for our success in the long-term. And by having the right team working on our objectives together, we believe this will be a rewarding experience for all of us.
You are an important member of the Bellerophon team. This letter confirms your future role as Senior Director, Business Development and Pharmaceutical Science with primarily responsibility for business development and pharmaceutical science . You will report directly to me. Your compensation package effective September 25, 2015 is highlighted below.
· Your base salary is $191,000.00
· Your annual bonus* target is 30%
Your bonus for 2015, normally paid in March 2016, will be paid by the end of January 2016 at 100% relative to target. It will be paid in the form of Bellerophon restricted shares that will fully vest in 12 months. The number of shares will be based on the closing price the day before the grant date. For future years we will revert to paying the bonus in March of the following year. It is our intent that we will continue to pay the annual bonus in shares with a one year vesting period.
You acknowledge and agree that you will be, and will remain, an employee at-will of Bellerophon, and that nothing in this letter is intended to be or create an obligation to employ you for any specific period of time. You further agree to hold all information relating to your compensation in strict confidence, and to not disclose this information to any party other than your financial or legal advisors.
I appreciate the commitment you have made to Bellerophon and to the patients we seek to help. I look forward to having you as part of the team.
Sincerely,
/s/ Jonathan Peacock
Jonathan Peacock
Chairman & CEO
	
				
	Acknowledged by:
	/s/ Parag Shah
	 
	21-Sept-2015

	 
	Employee Signature
	 
	Date






* Bonus payments are contingent on meeting or exceeding performance criteria established for your position and determined by your manager.
** Stock awards are contingent on the execution of a stock agreement which will be provided separately.


53 Frontage Road, Suite 301, Hampton, NJ 08827 | 908-574-4770 | bellerophon.com
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>                     <C>
<PERIOD-TYPE>                   3-MOS                   YEAR
<FISCAL-YEAR-END>            DEC-31-1998             DEC-31-1997
<PERIOD-END>                 MAR-31-1998             DEC-31-1997
<CASH>                          7,247                   7,247
<SECURITIES>                        0                       0
<RECEIVABLES>                  30,255                  30,255
<ALLOWANCES>                        0                       0
<INVENTORY>                         0                       0
<CURRENT-ASSETS>               37,502                  37,502
<PP&E>                              0                       0
<DEPRECIATION>                      0                       0
<TOTAL-ASSETS>                 37,502                  37,502
<CURRENT-LIABILITIES>       1,363,235               1,350,060
<BONDS>                             0                       0
<PREFERRED-MANDATORY>               0                       0
<PREFERRED>                         0                       0
<COMMON>                            0                       0
<OTHER-SE>                 (1,325,733)             (1,312,558)
<TOTAL-LIABILITY-AND-EQUITY>   37,502                  37,502
<SALES>                             0                       0
<TOTAL-REVENUES>                    0                     331
<CGS>                               0                       0
<TOTAL-COSTS>                       0                       0
<OTHER-EXPENSES>               13,175                  23,462
<LOSS-PROVISION>                    0                       0
<INTEREST-EXPENSE>                  0                       0
<INCOME-PRETAX>               (13,175)                (23,131)
<INCOME-TAX>                  (13,175)                (23,131)
<INCOME-CONTINUING>                 0                       0
<DISCONTINUED>                      0                       0
<EXTRAORDINARY>                     0                       0
<CHANGES>                           0                       0
<NET-INCOME>                  (13,175)                (23,131)
<EPS-PRIMARY>                       0                       0
<EPS-DILUTED>                       0                       0
        

</TABLE>
UN PUBLISHED
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 22
- 7390

UNITED STATES OF AMERICA , Plaintiff

- Appellee ,

v. HILTON THOMAS, a/k/a Dinkles , Defendant

- Appellant

.

Appeal from the United States District Court for the District of Maryland , at Baltimore

. James K. Bredar, Chief District Judge. ( 1:97

- cr - 00355

- JKB

- 3 )

Submitted : April 25, 2023 Decided: April 28, 2023

Before GREGORY , Chief Judge, THACKER, Circuit Judge , and MOTZ, Senior Circuit Judge

.
Affirmed by un published per curiam opinion

.
Hilton Thomas , Appellant Pro Se. Michael Clayton Hanlon, Assistant United States Attorney, OFFICE OF THE UNITED STATES ATTORNEY, Baltimo re, Maryland, for Appellee.
Unpublished opinions are not binding precedent in this circuit. USCA4 Appeal: 22-7390 Doc: 11 Filed: 04/28/2023 Pg: 1 of 22 PER CURIAM: Hilton Thomas appeals the district court’s order denying his 18 U.S.C. § 3582(c)(1)(A) motion for compassionate release. We review a district cou rt’s denial of a compassionate release motion for abuse of discretion. United States v. Kibble , 992 F.3d 326, 329 (4th Cir.), cert. denied , 142 S. Ct. 383 (2021). We have reviewed the record and conclude that the court did not abuse its discretion in den ying relief. See United States v. High , 997 F.3d 181, 188

- 91 (4th Cir. 2021) (discussing amount of explanation required for denial of compassionate release motion). Accordingly, we affirm the district court’s order. United States v. Thomas , No. 1:97

- cr - 00355

- JKB

- 3 (D. Md. Nov. 17, 2022). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before this court and argument would not aid the decisional process.
AFFIRMED USCA4 Appeal: 22-7390 Doc: 11 Filed: 04/28/2023 Pg: 2 of 2
* Pursuant to 5 TH C IR

. R. 47.5, the court has determine d that

this opinion should not be published and is not precedent except

under the limited circumstances set forth in 5 TH C IR

. R. 47.5.4. UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 01-60935

DAVID DONNELL JACKSON,

Petitioner-Appellant,

versus

ROBERT ARMSTRONG,

Respondent-Appellee.

_________________________________________________________________

Appeal from the United States District Court

for the Southern District of Mississippi

(3:01-CV-584-BN)

_________________________________________________________________ May 23, 2002

Before HIGGINBOTHAM, WIENER, and BARKSDALE, Circuit Judges

PER CURIAM: *

David Donnell Jackson, Mississippi prisoner # 39640, seeks a

certificate of appealability (“COA”) to appeal the district court’s

dismissal without prejudice of his 28 U.S.C. § 2254 petition for

failure to exhaust his state remedies, pursuant to 28 U.S.C. §

2254(b)(1)(A). To obtain a COA, Jackson must make a substantial

showing of the denial of a constitutional right, which requires him

to show that “jurists of reason would find it debatable whether thepetition states a valid claim of the denial of a constitutional

right and that jurists of reason would find it debatable whether

the district court was correct in its procedural ruling.” S lack v.

McDaniel , 529 U.S. 473, 484 (2000); see 28 U.S.C. § 2253(c)(2).

Jackson argues that he should not be required to exhaust

because his state habeas application remains pending and has been

unduly delayed by the Mississippi Supreme Court. However, the

Mississippi Supreme Court clerk’s office confirms tha t Jackson’s

pos tconviction motion was denied on April 5, 2002, while the

instant appeal was pending. Because he has now exhausted his state

remedi es, COA is G RANTED

, the district court’s dismissal is

VACATED

, and the case is REMANDED for further proceedings on the

merits. S ee Sharpe v. Buchanan

, 317 U.S. 238, 238-39 (1942);

Bufalino v. Reno , 613 F.2d 568, 571 (5th Cir. 1980); M cDaniel v.

Sheriff of Dallas County , 445 F.2d 851, 852 (5th Cir. 1971).

COA GRANTED; CASE VACATED AND REMANDED
[Federal Register Volume 66, Number 121 (Friday, June 22, 2001)]
[Notices]
[Page 33579]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-15723]


=======================================================================
-----------------------------------------------------------------------

NATIONAL SCIENCE FOUNDATION


Business and Operations Advisory Committee; Notice of Meeting

    In accordance with Federal Advisory Committee Act (Pub. L. 92-463, 
as amended), the National Science Foundation announces the following 
meeting:

    Name: Business and Operations Advisory Committee (9556).
    Date/Time: July 18, 2001; 1:30-4:00 p.m. (EDT).
    Place: National Science Foundation, 4201 Wilson Boulevard, Room 
110, Arlington, VA.
    Type of Meeting: Open.
    Contact Person: Louise McIntire, National Science Foundation. 
4201 Wilson Boulevard, Arlington, VA 22230 (703) 292-8200.
    Purpose of Meeting: Interim meeting as follow-up to the April 
26-27, 2001 meeting.

Agenda

July 18, 2001--1:30-4:00 p.m.

<bullet> Follow-up discussion on administrative and management 
planning at NSF
<bullet> Plans for Fall 2001 meeting
<bullet> Other business

    Dated: July 19, 2001.
Susanne Bolton,
Committee Management Officer.
[FR Doc. 01-15723 Filed 6-21-01; 8:45 am]
BILLING CODE 7555-01-M
Warren HAVENS, petitioner, v. MOBEX NETWORK SERVICES, LLC, et al.

No. 16-344.

Supreme Court of the United States

Nov. 28, 2016.

Petition for writ of certiorari to the United States Court of Appeals for the Third Circuit denied.
FORM 10-Q
Exhibit 31.1
**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**
I, Vincent A. Rego, certify that:
 1. I have reviewed this quarterly report on Form 10-Q of Encore WireCorporation;  2. Based on my knowledge, this quarterly report does not contain anyuntrue statement of a material fact or omit to state a material factnecessary to make the statements made, in light of the circumstancesunder which such statements were made, not misleading with respect tothe period covered by this quarterly report;  3. Based on my knowledge, the financial statements, and otherfinancial information included in this quarterly report, fairly presentin all material respects the financial condition, results of operationsand cash flows of the registrant as of, and for, the periods presentedin this quarterly report;  4. The registrant’s other certifying officers and I are responsiblefor establishing and maintaining disclosure controls and procedures (asdefined in Exchange Act Rules 13a-15(e) and 15d-15(e)), for theregistrant and have;
 a. designed such disclosure controls and procedures, orcaused such disclosure controls and procedures to be designedunder our supervision, to ensure that material informationrelating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within thoseentities, particularly during the period in which this quarterlyreport is being prepared;  b. evaluated the effectiveness of the registrant’sdisclosure controls and procedures and presented in thisquarterly report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the periodcovered by this quarterly report based on such evaluation; and  c. disclosed in this quarterly report any change in theregistrant’s internal control over financial reporting thatoccurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth quarter in the case of an annual report)that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control overfinancial reporting; and
 5. The registrant’s other certifying officers and I have disclosed,based on our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee ofregistrant’s board of directors (or persons performing the equivalentfunctions):
 

 

FORM 10-Q
 a. all significant deficiencies and material weaknessesin the design or operation of internal control over financialreporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize and reportfinancial information; and  b. any fraud, whether or not material, that involvesmanagement or other employees who have a significant role in theregistrant’s internal control over financial reporting.
Date: August 6, 2004            /s/ VINCENT A. REGO   Vincent A. Rego   *Chairman of the Board and*
Frank J. COZZARELLI, petitioner, v. SUPREME COURT OF NEW JERSEY.

No. 16-318.

Supreme Court of the United States

Oct. 31, 2016.

Petition for writ of certiorari to the Supreme Court of New Jersey denied.
Schedule A Trusts and Portfolios Covered by the Amended and Restated Sub-Advisory Agreement between Fidelity Management & Research Company LLC and Fidelity Management & Research (Japan) Limited   Name of TrustName of PortfolioType of FundEffective DateFidelity Garrison Street TrustFidelity Education FundFixed Income03/01/2024Fidelity Garrison Street TrustVIP Investment Grade Central FundFixed Income03/01/2024Fidelity Merrimack Street TrustFidelity Corporate Bond ETFFixed Income03/01/2024Fidelity Merrimack Street TrustFidelity Investment Grade Bond ETFFixed Income03/01/2024Fidelity Merrimack Street TrustFidelity Investment Grade Securitized ETFFixed Income03/01/2024Fidelity Merrimack Street TrustFidelity Limited Term Bond ETFFixed Income03/01/2024Fidelity Merrimack Street TrustFidelity Low Duration Bond ETFFixed Income03/01/2024Fidelity Merrimack Street TrustFidelity Low Duration Bond Factor ETFFixed Income03/01/2024Fidelity Merrimack Street TrustFidelity Municipal Bond Opportunities ETFFixed Income09/19/2024Fidelity Merrimack Street TrustFidelity Systematic Municipal Bond Index ETFFixed Income09/19/2024Fidelity Merrimack Street TrustFidelity Total Bond ETFFixed Income03/01/2024Fidelity Revere Street TrustFidelity Cash Central FundMoney Market03/01/2024Fidelity Revere Street TrustFidelity Municipal Cash Central FundMoney Market03/01/2024Fidelity Revere Street TrustFidelity Securities Lending Cash Central FundMoney Market03/01/2024Fidelity Revere Street TrustFidelity Tax-Free Cash Central FundMoney Market03/01/2024     Fidelity Management & Research Company LLCFidelity Management & Research (Japan) LimitedBy: /s/ Christopher J. RimmerBy: /s/ Kirk Roland NeureiterName: Christopher J. RimmerName: Kirk Roland NeureiterTitle: TreasurerTitle: Director